Stocks / NASDAQ / Carbylan Therapeutics, Inc.

Carbylan Therapeutics, Inc.

Our Opinion

KalVista Pharmaceuticals is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

KalVista Pharmaceuticals, Inc. FORM S-1 2014

The following report cites that the company uses animals for product testing. “Concurrent with clinical trials, companies may complete additional animal studies, develop additional information about the chemistry and physical characteristics of the drug and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.” (Page 97)

Company Description

As of November 21, 2016, Carbylan Therapeutics, Inc. was acquired by KalVista Pharmaceuticals, Inc., in a reverse merger transaction. Carbylan Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of novel and proprietary combination therapies. Its product candidate is Hydros-TA, which is in Phase III clinical trial designed to provide rapid and sustained relief from pain associated with osteoarthritis. The company was formerly known as Carbylan Biosurgery, Inc. and changed its name to Carbylan Therapeutics, Inc. in March 2014. Carbylan BioSurgery, Inc. was founded in 2004 and is headquartered in Palo Alto, California. [source: Bloomberg]

Company Website: http://www.kalvista.com